Long-term treatment of multiple sclerosis with IgG immunotherapy

被引:0
|
作者
Schuller, E [1 ]
Lambin, P [1 ]
Deloche, G [1 ]
机构
[1] HOP LA PITIE SALPETRIERE,INTS,LAB IMMUNOCHEM,F-75651 PARIS 13,FRANCE
来源
PATHOLOGIE BIOLOGIE | 1996年 / 44卷 / 08期
关键词
multiple sclerosis; IgG therapy; long-term open trial;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Thirty-five patients with a clinically [1] definite multiple sclerosis (M.S.) were treated in an open trial(1975 - 1993) with a standard dose preparation of total IgG (5 grams per week) by intra-muscular or intravenous injection. This treatment was used in 35 patients : during 3 to 16 years, Using Kurtzke's distability scale the results were : I) a significant deterioration (loss of 1 grade in the Kurtzke disability scale) only 14 years after the entry in the trial. 2) regarding current therapeutic results : improvement for 8 patients, deterioration fur 18, and stability for 9. Neither ?he age at the M.S. onset and at the entry, nor the duration of the disease, nor the disability score at the entry were factors modifying significantly the efficacy of the treatment. The comparison of these results with previous predictive studies (Confavreux, Weinshenker) suggests a significant reduction of M.S. progression, with an increase of-the functional independence period, No side-effects were observed and this immunotherapy, which may be convenient for home care. must be tested in properly controlled trials.
引用
收藏
页码:710 / 715
页数:6
相关论文
共 50 条
  • [21] long-term retrospective analysis of multiple sclerosis treatment and disability outcomes
    Arnett, Simon
    Chew, Sin Hong
    Sobarun, Namrata
    Prosser, Michelle
    o'maley, Timothy
    Broadley, Simon
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 613 - 613
  • [22] Drug Choice of Long-Term Treatment of Patients with Multiple Sclerosis.
    Liu, Yonghong
    Zhou, Heng
    Wang, Huabing
    Ma, Yuetao
    Cao, Jingbo
    Liu, Yun
    Song, Tian
    Gong, Xiaoqing
    Zhou, Anna
    Zhao, Lin
    Zhang, Xinghu
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 436 - 436
  • [23] Progression to disability milestones in multiple sclerosis with long-term natalizumab treatment
    Trojano, Maria
    Butzkueven, Helmut
    Kappos, Ludwig
    Wiendl, Heinz
    Spelman, Tim
    Pellegrini, Fabio
    Pellegrini, Fabio
    Dong, Qunming
    Kondgen, Harold
    Belachew, Shibeshih
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP2 - NP2
  • [24] Long-term drug treatment in multiple sclerosis: safety success and concerns
    Jakimovski, Dejan
    Vaughn, Caila B.
    Eckert, Svetlana
    Zivadinov, Robert
    Weinstock-Guttman, Bianca
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (09) : 1121 - 1142
  • [25] Risk of myelodysplastic syndrome in long-term treatment with azathioprine in multiple sclerosis
    Putzki, N
    Knipp, S
    Ramczykowski, T
    Vago, S
    Diener, H
    Limmroth, V
    JOURNAL OF NEUROLOGY, 2005, 252 : 40 - 40
  • [26] LONG-TERM TREATMENT USING BACLOFEN IN A CENTER FOR MULTIPLE-SCLEROSIS
    BANESSY, H
    GAZETTE MEDICALE DE FRANCE, 1982, 89 (01): : 74 - 76
  • [27] Long-term fingolimod treatment in two pediatric patients with multiple sclerosis
    Borriello, Giovanna
    Pozzilli, Carlo
    NEUROLOGICAL SCIENCES, 2021, 42 (SUPPL 1) : 29 - 36
  • [28] LONG-TERM EFFECT OF ACTH TREATMENT OF RELAPSE IN MULTIPLE-SCLEROSIS
    HOOGSTRATEN, MC
    MINDERHOUD, JM
    ACTA NEUROLOGICA SCANDINAVICA, 1990, 82 (01): : 74 - 77
  • [29] Progression to disability milestones in multiple sclerosis with long-term natalizumab treatment
    Trojano, M.
    Butzkueven, H.
    Kappos, L.
    Wiendl, H.
    Spelman, T.
    Pellegrini, F.
    Chen, Y.
    Dong, Q.
    Koendgen, H.
    Belachew, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 562 - 563
  • [30] Can we measure long-term treatment effects in multiple sclerosis?
    Maria Pia Sormani
    Paolo Bruzzi
    Nature Reviews Neurology, 2015, 11 : 176 - 182